Table 2.
Effects of rosuvastatin on measures of thrombin generation parameters
| Mean levels (SD) | Mean* | Mean difference† | Mean‡ | Mean difference§ | ||
|---|---|---|---|---|---|---|
| Baseline | End of study | change (95% CI) | in change (95% CI) | change (95% CI) | in change (95% CI) | |
| Thrombin generation | ||||||
| ETP (nm*min) | ||||||
| Non‐users | 1245.01 (321.47) | 1343.85 (290.17) | 97.22 (40.92, 153.53) | Reference | 94.62 (37.78, 151.46) | Reference |
| Rosuvastatin users | 1284.04 (263.97) | 1259.10 (205.37) | −24.94 (−71.81, 21.93) | −120.24 (−192.97, −47.51) | −38.49 (−85.19, 8.21) | −129.39 (−202.29, −56.49) |
| Thrombin peak (nm) | ||||||
| Non‐users | 273.33 (62.09) | 294.47 (52.32) | 20.69 (9.80, 31.58) | Reference | 20.39 (9.42, 31.37) | Reference |
| Rosuvastatin users | 288.86 (62.68) | 297.27 (52.25) | 8.41 (−0.86, 17.69) | −11.88 (−26.11, 2.35) | 5.99 (−3.31, 15.29) | −13.69 (−27.98, 0.60) |
| Lag time (min) | ||||||
| Non‐users | 2.23 (0.49) | 2.19 (0.72) | −0.04 (−0.16, 0.08) | Reference | −0.04 (−0.17, 0.08) | Reference |
| Rosuvastatin users | 2.16 (0.43) | 2.05 (0.38) | −0.11 (−0.15, −0.07) | −0.07 (−0.20, 0.05) | −0.12 (−0.16, −0.08) | −0.08 (−0.21, 0.05) |
| Time to peak (min) | ||||||
| Non‐users | 4.55 (0.89) | 4.48 (1.06) | −0.07 (−0.23, 0.09) | Reference | −0.06 (−0.22, 0.10) | Reference |
| Rosuvastatin users | 4.37 (0.77) | 4.09 (0.71) | −0.28 (−0.35, −0.21) | −0.21 (−0.38, −0.03) | −0.28 (−0.35, −0.21) | −0.22 (−0.39, −0.04) |
| Velocity index | ||||||
| Non‐users | 126.68 (47.07) | 137.39 (43.90) | 10.37 (3.64, 17.09) | Reference | 9.96 (3.15, 16.77) | Reference |
| Rosuvastatin users | 140.33 (57.35) | 154.69 (50.87) | 14.36 (7.38, 21.34) | 4.41 (−5.35, 14.17) | 12.52 (5.60, 19.44) | 3.07 (−6.66, 12.80) |
SD, standard deviation; ETP, endogenous thrombin potential. *Paired analysis. †Between comparison analysis, adjusted for age and sex. ‡Paired analysis to eight participants who reported an infection at time of end of study excluded. §Between comparison analysis, adjusted for age and sex to eight participants who reported an infection at time of end of study excluded.